Dogwood Therapeutics (DWTX) Competitors $2.34 +0.02 (+0.86%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends DWTX vs. NRSN, IPA, IMNN, CRVO, RLMD, KZIA, TLPH, SNSE, KPRX, and CSCIShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include NeuroSense Therapeutics (NRSN), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), CervoMed (CRVO), Relmada Therapeutics (RLMD), Kazia Therapeutics (KZIA), Talphera (TLPH), Sensei Biotherapeutics (SNSE), Kiora Pharmaceuticals (KPRX), and COSCIENS Biopharma (CSCI). These companies are all part of the "pharmaceutical preparations" industry. Dogwood Therapeutics vs. NeuroSense Therapeutics ImmunoPrecise Antibodies Imunon CervoMed Relmada Therapeutics Kazia Therapeutics Talphera Sensei Biotherapeutics Kiora Pharmaceuticals COSCIENS Biopharma Dogwood Therapeutics (NASDAQ:DWTX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability. Which has more risk and volatility, DWTX or NRSN? Dogwood Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Is DWTX or NRSN more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A -217.12% -172.06% NeuroSense Therapeutics N/A N/A -286.31% Does the media refer more to DWTX or NRSN? In the previous week, NeuroSense Therapeutics had 10 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 10 mentions for NeuroSense Therapeutics and 0 mentions for Dogwood Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.20 beat Dogwood Therapeutics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dogwood Therapeutics Neutral NeuroSense Therapeutics Neutral Do institutionals & insiders hold more shares of DWTX or NRSN? 9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 12.2% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in DWTX or NRSN? NeuroSense Therapeutics received 2 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformDogwood TherapeuticsN/AN/ANeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% Which has higher valuation & earnings, DWTX or NRSN? NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$5.30M-$6.55-0.36NeuroSense TherapeuticsN/AN/A-$11.28M-$0.85-1.60 Do analysts rate DWTX or NRSN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryNeuroSense Therapeutics beats Dogwood Therapeutics on 8 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.12M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.3610.5990.0517.18Price / SalesN/A196.061,116.25117.06Price / CashN/A57.1643.1037.85Price / Book0.475.094.784.78Net Income-$5.30M$151.83M$120.31M$225.60M7 Day Performance-0.85%-2.14%-1.92%-1.23%1 Month Performance-8.24%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood TherapeuticsN/A$2.34+0.9%N/AN/A$3.12MN/A-0.364NRSNNeuroSense Therapeutics0.4931 of 5 stars$0.89+3.8%N/A+75.0%$12.20MN/A-0.9518Earnings ReportGap DownIPAImmunoPrecise Antibodies2.954 of 5 stars$0.42+4.4%$5.00+1,087.6%-69.5%$12.14M$24.07M-0.5280News CoverageIMNNImunon2.3547 of 5 stars$0.84-1.1%$20.50+2,355.1%+9.2%$12.11M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpCRVOCervoMed2.1768 of 5 stars$1.92+1.1%$42.00+2,087.5%-67.1%$11.85M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeRLMDRelmada Therapeutics4.19 of 5 stars$0.38+3.5%$4.25+1,018.4%-87.7%$11.47MN/A-0.1310Gap DownHigh Trading VolumeKZIAKazia Therapeutics1.7282 of 5 stars$3.42-3.7%$20.00+484.8%-21.6%$11.39M$2.31M0.0012Gap UpTLPHTalphera2.8842 of 5 stars$0.67+2.8%$4.50+573.1%N/A$11.38M$281,000.00-0.9419Positive NewsSNSESensei Biotherapeutics4.077 of 5 stars$0.44+1.0%$4.33+874.9%-28.6%$11.18MN/A-0.3740Positive NewsGap DownKPRXKiora Pharmaceuticals2.1034 of 5 stars$3.64+9.6%$10.00+174.7%-32.5%$10.92M$16M0.0010Positive NewsGap UpCSCICOSCIENS BiopharmaN/A$2.90flatN/AN/A$10.90M$7.60M-0.24N/AGap Down Related Companies and Tools Related Companies NRSN Alternatives IPA Alternatives IMNN Alternatives CRVO Alternatives RLMD Alternatives KZIA Alternatives TLPH Alternatives SNSE Alternatives KPRX Alternatives CSCI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DWTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
